Sutro Biopharma (NASDAQ:STRO) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Sutro Biopharma (NASDAQ:STRO) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

A number of other equities research analysts also recently commented on STRO. Wells Fargo & Company reduced their target price on Sutro Biopharma from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 12th. Wedbush reiterated a “neutral” rating and set a $2.00 price target on shares of Sutro Biopharma in a research report on Friday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Sutro Biopharma in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $4.47.

Sutro Biopharma Stock Performance

Shares of Sutro Biopharma stock opened at $0.81 on Friday. The business’s 50 day moving average price is $0.95 and its 200 day moving average price is $0.88. The company has a market cap of $68.63 million, a price-to-earnings ratio of -0.31 and a beta of 1.75. Sutro Biopharma has a one year low of $0.52 and a one year high of $4.60.

Sutro Biopharma (NASDAQ:STRO) last issued its earnings results on Thursday, November 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.25). Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. The company had revenue of $9.69 million during the quarter, compared to analysts’ expectations of $10.14 million. On average, analysts predict that Sutro Biopharma will post -2.92 EPS for the current fiscal year.

Insider Activity

In other news, Director Connie Matsui bought 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The stock was purchased at an average cost of $0.80 per share, with a total value of $40,000.00. Following the transaction, the director directly owned 50,000 shares in the company, valued at $40,000. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders bought 111,754 shares of company stock valued at $89,601. 5.90% of the stock is owned by corporate insiders.

Institutional Trading of Sutro Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. Cerity Partners LLC purchased a new position in Sutro Biopharma during the 1st quarter worth $25,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Sutro Biopharma in the 2nd quarter valued at approximately $27,000. Savant Capital LLC acquired a new position in shares of Sutro Biopharma in the second quarter valued at approximately $37,000. CWM LLC increased its holdings in shares of Sutro Biopharma by 73.2% in the second quarter. CWM LLC now owns 56,657 shares of the company’s stock valued at $40,000 after purchasing an additional 23,941 shares during the period. Finally, Vanguard Personalized Indexing Management LLC raised its stake in shares of Sutro Biopharma by 174.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company’s stock worth $43,000 after purchasing an additional 38,561 shares during the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.